Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own1.00% Shs Outstand290.87M Perf Week-5.08%
Market Cap6.08B Forward P/E41.49 EPS next Y0.50 Insider Trans-31.70% Shs Float273.43M Perf Month-3.82%
Income-70.20M PEG- EPS next Q-0.02 Inst Own82.80% Short Float7.47% Perf Quarter28.13%
Sales191.50M P/S31.76 EPS this Y63.70% Inst Trans8.67% Short Ratio3.87 Perf Half Y41.86%
Book/sh0.31 P/B67.45 EPS next Y888.24% ROA-13.30% Target Price25.00 Perf Year417.57%
Cash/sh1.44 P/C14.49 EPS next 5Y46.00% ROE127.20% 52W Range3.64 - 23.49 Perf YTD40.24%
Dividend- P/FCF29.73 EPS past 5Y-19.90% ROI-15.10% 52W High-10.98% Beta1.93
Dividend %- Quick Ratio1.70 Sales past 5Y-7.90% Gross Margin96.60% 52W Low474.45% ATR0.96
Employees287 Current Ratio1.70 Sales Q/Q683.80% Oper. Margin-21.90% RSI (14)47.23 Volatility4.44% 4.57%
OptionableYes Debt/Eq2.12 EPS Q/Q166.70% Profit Margin-36.70% Rel Volume0.63 Prev Close20.31
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 AMC Payout- Avg Volume5.28M Price20.91
Recom2.00 SMA20-4.37% SMA500.87% SMA20046.08% Volume3,344,198 Change2.95%
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Mar-16-17 09:30AM  When Profit Makers Can Be Active Profit Takers Accesswire
07:36AM  Coverage initiated on Exelixis by Oppenheimer
Mar-15-17 08:21AM  Why Exelixis Is Already Up 55% This Year at Motley Fool
Mar-14-17 07:23AM  The 3 Most Important Numbers for Exelixis, Inc. at Motley Fool
Mar-13-17 10:11AM  Top Stocks That Are Already Crushing the Market in 2017 at Motley Fool
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-07-17 05:42PM  Is Exelixis' Balance Sheet Safe? at Motley Fool
08:47AM  3 Factors That Drove Exelixis, Inc. Higher By 19% in February at Motley Fool
Mar-06-17 01:39PM  ETFs with exposure to Exelixis, Inc. : March 6, 2017
09:04AM  Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma Business Wire
Mar-04-17 07:25PM  Icahn's (Potential) Move Into Biotech
Mar-03-17 01:04PM  EXELIXIS, INC. Financials
08:15AM  Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland Accesswire
Mar-02-17 11:47AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
09:30AM  Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Mar-01-17 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
03:19PM  M&As, Pipeline Catalysts to Drive Pharma Sector
10:40AM  Exelixis, Inc. Turns a Profit, but Don't Get Too Excited at Motley Fool
09:02AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
Feb-28-17 06:15PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire -6.76%
04:13PM  Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive
11:46AM  Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
10:50AM  Exelixis 4Q Net 12 Cents a Share Vs Loss Last Year at Investopedia
10:17AM  Exelixis In Cancer Deals With Roche, Bristol Myers at Investopedia
09:30AM  Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
02:42AM  Edited Transcript of EXEL earnings conference call or presentation 27-Feb-17 10:00pm GMT
Feb-27-17 05:18PM  Exelixis tops Street 4Q forecasts +6.45%
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:34PM  Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team
04:11PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
04:05PM  Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update Business Wire
12:02PM  Exelixis shares jump after team up with Bristol-Myers on cancer trials at CNBC
08:56AM  Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
07:07AM  Q4 2016 Exelixis Inc Earnings Release - After Market Close
07:01AM  Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors Business Wire
06:59AM  Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma Business Wire
06:44AM  4 Stocks to Buy with Superb Earnings Acceleration
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
08:38AM  Why Earnings Season Could Be Great for Exelixis (EXEL)
07:49AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
Feb-23-17 04:43PM  Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
04:23PM  Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
04:16PM  ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
09:45AM  TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
Feb-22-17 03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
08:16AM  Can Penumbra (PEN) Spring a Surprise this Earnings Season?
Feb-21-17 08:46AM  Patterson Companies (PDCO) Q3 Earnings: What's in Store?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
05:15AM  Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Feb-17-17 05:02PM  Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
02:30PM  Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
09:30AM  Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis Accesswire
Feb-15-17 02:44PM  Two Great Stock Ideas in the IBB Biotech ETF at Investopedia
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-10-17 09:42AM  Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
09:30AM  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
04:10AM  Exelixis (EXEL) Shares March Higher, Can It Continue?
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
10:15AM  Ecolab (ECL): What's in the Cards this Earnings Season?
09:27AM  Buy 4 Stocks Riding High on Superb Earnings Acceleration
07:39AM  5 Drug Stocks Poised to Beat Earnings Estimates in Q4
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.06%
01:49PM  Four Biotech Stocks Breaking Out at Forbes
10:10AM  DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 Business Wire
03:26PM  5 Great Biotech Stocks to Buy Now
07:41AM  4 Drug Stocks that are Broker Favorites
Feb-03-17 11:17AM  Hopes for Tax Reform, Less Regulation Lift Indices +8.40%
Feb-02-17 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 Business Wire
07:37AM  2 Big Reasons Exelixis, Inc. Soared 22% in January at Motley Fool
Feb-01-17 08:15AM  Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Accesswire
Jan-31-17 04:05PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
11:24AM  Exelixis, Takeda Sign Japanese Cancer Drug Deal at Investopedia
07:00AM  Exelixis Inks Partnership with Takeda for Cabometyx in Japan
Jan-30-17 06:00PM  Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Business Wire
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 09:45AM  Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Accesswire
Jan-23-17 05:27PM  Better Buy: Exelixis, Inc. vs. Novartis at Motley Fool
Jan-11-17 10:49AM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : January 11, 2017
Jan-10-17 12:21PM  After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next at Motley Fool +7.57%
09:27AM  4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
09:20AM  Genentech Withdraws Cost Claims Against Exelixis at Investopedia
07:23AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017
Jan-09-17 04:14PM  Why Exelixis, Inc. Stock Zoomed Higher Today at Motley Fool +14.75%
07:25AM  3 Stocks Expected to More Than Double Their Earnings in 2017 at Motley Fool
05:13AM  Update on Dispute between Exelixis and Genentech, a Member of the Roche Group Business Wire
Jan-05-17 09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
Jan-04-17 09:15AM  Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis Accesswire
08:49AM  How calls are looking for Exelixis rally
07:24AM  Is It Too Late to Buy Exelixis Stock? at Motley Fool
Jan-03-17 06:07PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
02:04PM  ETFs with exposure to Exelixis, Inc. : January 3, 2017
10:08AM  Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year at Motley Fool
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
08:25AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
SPSC SPS Commerce, Inc. daily Stock Chart
SPSC [NASD]
SPS Commerce, Inc.
Index- P/E171.15 EPS (ttm)0.33 Insider Own0.90% Shs Outstand17.18M Perf Week-0.69%
Market Cap970.33M Forward P/E56.03 EPS next Y1.01 Insider Trans-31.50% Shs Float17.08M Perf Month-0.41%
Income5.70M PEG7.61 EPS next Q0.19 Inst Own- Short Float2.78% Perf Quarter-20.19%
Sales193.30M P/S5.02 EPS this Y21.60% Inst Trans-0.48% Short Ratio2.99 Perf Half Y-23.07%
Book/sh14.63 P/B3.86 EPS next Y22.93% ROA2.00% Target Price75.44 Perf Year43.93%
Cash/sh8.09 P/C6.98 EPS next 5Y22.50% ROE2.40% 52W Range38.35 - 74.85 Perf YTD-19.19%
Dividend- P/FCF89.85 EPS past 5Y-21.00% ROI1.80% 52W High-24.54% Beta1.17
Dividend %- Quick Ratio5.80 Sales past 5Y27.20% Gross Margin66.70% 52W Low47.28% ATR1.42
Employees1217 Current Ratio5.80 Sales Q/Q20.80% Oper. Margin3.90% RSI (14)45.58 Volatility2.73% 2.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-17.30% Profit Margin3.00% Rel Volume0.63 Prev Close56.27
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 AMC Payout0.00% Avg Volume158.48K Price56.48
Recom2.10 SMA202.02% SMA50-7.13% SMA200-12.78% Volume99,114 Change0.37%
Feb-08-17Downgrade Pacific Crest Overweight → Sector Weight
Feb-08-17Downgrade Canaccord Genuity Buy → Hold $82 → $65
Dec-06-16Initiated The Benchmark Company Buy $84
Sep-30-16Initiated Pacific Crest Overweight $85
Sep-27-16Initiated First Analysis Sec Overweight $86
Sep-26-16Reiterated Needham Buy $70 → $83
Jul-27-16Reiterated Needham Buy $60 → $70
Jul-24-15Reiterated Stifel Buy $80 → $85
Jul-24-15Reiterated Northland Capital Outperform $82 → $87
Jul-24-15Reiterated Canaccord Genuity Buy $80 → $83
Jul-23-15Reiterated Needham Buy $72 → $86
Jun-28-13Reiterated Stifel Buy $46 → $60
Apr-26-13Reiterated Northland Capital Outperform $43 → $48
Apr-02-13Initiated Maxim Group Buy $50
Oct-26-12Reiterated Needham Buy $37 → $43
Oct-22-12Upgrade Canaccord Genuity Hold → Buy $45
Aug-08-12Reiterated Needham Buy $34 → $37
Jun-21-12Initiated Northland Securities Outperform $34
Feb-09-12Reiterated Stifel Nicolaus Buy $25 → $32
Feb-09-12Reiterated JMP Securities Mkt Outperform $21 → $29
Mar-03-17 01:04PM  SPS COMMERCE INC Financials
Feb-27-17 05:26PM  SPS COMMERCE INC Files SEC form 10-K, Annual Report
Feb-21-17 09:00AM  SPS Commerce to Present at the JMP Securities 2017 Technology Conference GlobeNewswire
Feb-15-17 04:26PM  SPS COMMERCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-09-17 12:17PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017
Feb-08-17 12:42PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 -18.86%
07:12AM  SPS Commerce downgraded by Pacific Crest and Canaccord Genuity
Feb-07-17 08:05PM  Edited Transcript of SPSC earnings conference call or presentation 7-Feb-17 9:30pm GMT
06:23PM  SPS Commerce beats Street 4Q forecasts AP
04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 SPS Commerce Inc Earnings Release - After Market Close
Feb-01-17 03:03PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : February 1, 2017
Jan-31-17 10:13AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : January 31, 2017
Jan-26-17 02:20PM  More Retailers Get on Board With 'Drop Shipping' for E-Commerce at The Wall Street Journal
Jan-24-17 09:00AM  SPS Commerce In:fluence 2017 Empowers Attendees to Go Beyond with Inspirational Keynote Speakers GlobeNewswire
Jan-17-17 04:05PM  SPS Commerce Announces Date of Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Jan-16-17 08:00AM  Retail Industry Moving Beyond Omnichannel as Consumers Demand Personalized Shopping Experiences Across Channels GlobeNewswire
Jan-10-17 09:10AM  SPS Commerce and Deposco Deliver Orchestrated Retail Solutions to Advance the Digital Supply Chain GlobeNewswire
Jan-03-17 04:05PM  SPS Commerce to Present at the 19th Annual Needham Growth Conference GlobeNewswire
Dec-21-16 06:57AM  Avis Closes France Cars Buyout to Boost Global Presence
Dec-19-16 08:35AM  Xerox's (XRX) Strategic Efforts Bode Well, Risks Remain
Dec-12-16 02:35AM  SPS Commerce, Inc. (SPSC): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-02-16 11:06AM  ETFs with exposure to SPS Commerce, Inc. : December 2, 2016
Dec-01-16 07:16AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : December 1, 2016
Nov-10-16 09:30AM  Zacks.com featured highlights: SPS Commerce, CryoLife, FormFactor, Willdan Group and LegacyTexas Financial Group
Nov-09-16 08:01AM  Focus On 5 Best Profitable Stocks for Desirable Returns
Nov-04-16 09:30AM  Zacks.com featured highlights: Activision Blizzard, Gibraltar Industries, Northrop Grumman, SJW and SPS Commerce
Nov-03-16 10:15AM  Follow Driehaus' Rule & Pick These 5 Momentum Stocks
Oct-28-16 07:17PM  Edited Transcript of SPSC earnings conference call or presentation 27-Oct-16 8:30pm GMT -7.22%
04:05PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Oct-27-16 07:05PM  SPS Commerce tops Street 3Q forecasts AP
04:09PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 SPS Commerce Inc Earnings Release - After Market Close
Oct-26-16 09:14AM  Business Service Stocks Earnings on Oct 27: EXLS, FCN & More
Oct-25-16 05:05PM  Breakout Watch: RealPage Rallies Into Buy Zone Ahead Of Earnings
Oct-21-16 08:51AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : October 21, 2016
Oct-06-16 04:05PM  SPS Commerce Announces Date of Third Quarter 2016 Financial Results GlobeNewswire
Sep-30-16 04:54PM  Four Top Software Stocks That Are Tough To Top
Sep-22-16 08:35AM  SPS Commerce (SPSC) in Focus: Stock Jumps 6.5% in Session
Sep-21-16 12:30AM  IHS Tears Down the iPhone 7, Mast Therapeutics Crashes On Trial Failure, Plus the Latest Hype On 3 Other Stocks at Insider Monkey +6.53%
Sep-20-16 06:14PM  The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600 PR Newswire
Sep-19-16 10:46AM  ETFs with exposure to SPS Commerce, Inc. : September 19, 2016
Sep-16-16 09:29AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016
Aug-03-16 04:05PM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
09:24AM  Avis (CAR) Q2 Earnings Miss, Stock Up on Raised 2016 View
Jul-29-16 04:23PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Jul-28-16 08:11AM  Edited Transcript of SPSC earnings conference call or presentation 27-Jul-16 8:30pm GMT
07:25AM  SPS Commerce tops Street 2Q forecasts AP
Jul-27-16 04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Second Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 SPS Commerce Inc Earnings Release - After Market Close
Jul-06-16 04:05PM  SPS Commerce Announces Date of Second Quarter 2016 Financial Results GlobeNewswire
Jun-30-16 04:06PM  ETFs with exposure to SPS Commerce, Inc. : June 30, 2016
Jun-28-16 02:01PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016
May-26-16 04:05PM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
May-18-16 05:32PM  SPS COMMERCE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-04-16 06:01PM  5 Best States for Tech Jobs (SPSC, AMZN) at Investopedia
Apr-29-16 04:12PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Apr-27-16 10:30AM  Leading Retailers and Brands Turn to SPS Commerce Fulfillment to Advance Beyond EDI for the Digital Retail Era GlobeNewswire
Apr-26-16 02:08PM  ETFs with exposure to SPS Commerce, Inc. : April 26, 2016
Apr-25-16 10:57AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q1, 2016 By the Numbers
Apr-22-16 04:46PM  Edited Transcript of SPSC earnings conference call or presentation 21-Apr-16 8:30pm GMT
Apr-21-16 05:11PM  SPS Commerce beats Street 1Q forecasts
04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  SPS Commerce Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 SPS Commerce Inc Earnings Release - After Market Close CCBN
Apr-19-16 11:21AM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : April 19, 2016
Apr-18-16 11:46AM  Cvent Takeout Shines Spotlight on Cloud Software Providers at TheStreet
08:05AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : April 18, 2016
Apr-12-16 09:00AM  Leading Retail Executives to Inform and Inspire Digital Retail Transformation at SPS Commerce In:fluence 2016 GlobeNewswire
Apr-07-16 04:05PM  SPS Commerce Announces Date of First Quarter 2016 Financial Results GlobeNewswire
Mar-29-16 04:36PM  Retail Technology Experts Pave the Way for Industry Transformation at SPS Commerce In:fluence 2016 at noodls
04:05PM  Retail Technology Experts Pave the Way for Industry Transformation at SPS Commerce In:fluence 2016 GlobeNewswire
Mar-24-16 10:51AM  Sierra Sage builds powerful business relationship via SPS In:fluence at noodls
Mar-23-16 12:04PM  SPS Commerce heading to 2016 SUN Conference at noodls
Feb-24-16 05:27PM  SPS COMMERCE INC Files SEC form 10-K, Annual Report
Feb-22-16 04:05PM  SPS Commerce to Present at the JMP Securities Technology Conference GlobeNewswire
Feb-15-16 09:00AM  SPS Commerce In:fluence 2016 Keynote Speakers Set to Inspire the Retail Industry GlobeNewswire
Feb-11-16 03:44PM  SPS Commerce feels the squeeze of a tightening labor market at bizjournals.com
Feb-08-16 10:22AM  SPS Commerce, Inc. Earnings Analysis: 2015 By the Numbers -5.74%
Feb-04-16 04:58PM  SPS Commerce (SPSC) Stock Price Target Cut at JMP Securities at TheStreet -20.25%
Feb-03-16 08:34PM  Edited Transcript of SPSC earnings conference call or presentation 3-Feb-16 9:30pm GMT
05:45PM  SPS Commerce tops Street 4Q forecasts AP
04:35PM  SPS COMMERCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:30PM  SPS Commerce Inc Earnings Call scheduled for 4:30 pm ET today
04:05PM  SPS Commerce Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
07:07AM  Q4 2015 SPS Commerce Inc Earnings Release - After Market Close
Jan-29-16 09:21AM  E-Commerce takes top priority over in-store experience at noodls
Jan-27-16 03:03PM  SPS Commerce named to Food Logistics FL100+ at noodls
Jan-20-16 04:05PM  SPS Commerce Announces Date of Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Jan-18-16 08:00AM  SPS Commerce Supercharges Retailers Merchandising Strategies Through Expanded Sourcing Offering GlobeNewswire
08:00AM  75 Percent of Retailers Rank E-Commerce Sales as a Top Priority, Displacing Stores for First Time GlobeNewswire
Jan-07-16 03:56PM  SPS Commerce Needs More Than ToolBox In This Market at Investor's Business Daily
03:40PM  Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial at Investor's Business Daily
Jan-06-16 07:56AM  SPS COMMERCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
07:30AM  SPS Commerce Acquires ToolBox Solutions GlobeNewswire
Jan-05-16 04:05PM  SPS Commerce to Present at the Needham Growth Conference GlobeNewswire
Dec-29-15 03:30PM  4 More Overvalued Stocks That Are Best Ignored
SPS Commerce, Inc. provides cloud-based supply chain management solutions worldwide. It provides solutions through the SPS Commerce platform, a cloud-based product suite that enhances the way suppliers, retailers, distributors, logistics firms, and other trading partners manage and fulfill orders. The company offers Trading Partner Fulfillment solution, which provides fulfillment automation and replaces or augments an organization's existing trading partner electronic communication infrastructure; Trading Partner Analytics solution that comprises data analytics applications to enhance visibility and analysis of customers supply chains; and Trading Partner Assortment solution to manage individual attributes associated with each item a retailer or supplier sells. It also provides Trading Partner Sourcing solution that enables retailers to source providers of new items, suppliers to connect with new retailers, and retailing community to make connections for expanding their business networks and grow; Trading Partner Community Development solution, which offers communications programs that enables retailers, suppliers, and emerging providers of value-added products and services to establish trading partner relationships with new trading partners to expand their businesses; and Other Trading Partner Solutions, such as barcode labeling, planogram services, and scan and pack application that helps trading partners process information to streamline the picking and packaging process. The company sells its solutions primarily through retail sales professionals and supplier sales representatives to small- to mid-sized suppliers in the consumer packaged goods industry, as well as retailers, distributors, third-party logistics providers, and other trading partners. The company was formerly known as St. Paul Software, Inc. and changed its name to SPS Commerce, Inc. in May 2001. SPS Commerce, Inc. was incorporated in 1987 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Black Archie C.CEOMar 01Option Exercise16.6415,000249,600103,380Mar 03 06:05 PM
Black Archie C.CEOMar 01Sale55.8715,000837,99488,380Mar 03 06:05 PM
Frome James J.EVP & Chief Operating OfficerFeb 10Sale58.014,618267,88312,993Feb 14 08:10 PM
Frome James J.EVP & Chief Operating OfficerFeb 06Sale66.972,859191,46617,611Feb 08 05:18 PM
Black Archie C.CEOFeb 02Option Exercise16.645,37189,37373,971Feb 03 05:36 PM
Black Archie C.CEOFeb 02Sale68.135,371365,90368,600Feb 03 05:36 PM
Black Archie C.CEOFeb 01Option Exercise16.649,629160,22778,229Feb 03 05:36 PM
Black Archie C.CEOFeb 01Sale68.059,629655,23068,600Feb 03 05:36 PM
Black Archie C.CEOJan 04Option Exercise16.641,38523,04669,985Jan 05 05:26 PM
Black Archie C.CEOJan 04Sale70.031,38596,99568,600Jan 05 05:26 PM
Black Archie C.CEOJan 03Option Exercise16.6413,615226,55482,215Jan 05 05:26 PM
Black Archie C.CEOJan 03Sale69.2013,615942,11968,600Jan 05 05:26 PM
SORAN PHILIPDirectorNov 16Option Exercise27.552,67273,6147,938Nov 18 05:26 PM
SORAN PHILIPDirectorNov 16Sale66.282,672177,1025,266Nov 18 05:26 PM
Frome James J.EVP & Chief Operating OfficerNov 02Option Exercise25.323,94599,88724,415Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 02Sale62.193,945245,34120,470Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Option Exercise25.3212,023304,42232,493Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Sale62.2512,023748,47020,470Nov 03 05:11 PM
Black Archie C.CEOSep 02Option Exercise16.641,44824,09570,048Sep 06 05:16 PM
Smerklo Michael ADirectorSep 02Sale67.4058039,092760Sep 06 05:18 PM
Black Archie C.CEOSep 02Sale65.651,44895,06568,600Sep 06 05:16 PM
Black Archie C.CEOSep 01Option Exercise16.648,552142,30577,152Sep 06 05:16 PM
Black Archie C.CEOSep 01Sale65.268,552558,13468,600Sep 06 05:16 PM
LEESTMA MARTIN JDirectorAug 22Sale65.811,50098,7113,093Aug 24 04:25 PM
WEHRWEIN SVENDirectorAug 02Option Exercise8.963,02527,1106,493Aug 04 04:17 PM
WEHRWEIN SVENDirectorAug 02Sale64.993,025196,5944,593Aug 04 04:17 PM
Smerklo Michael ADirectorAug 02Sale65.7458138,1981,340Aug 04 04:15 PM
Black Archie C.CEOAug 01Option Exercise16.6410,000166,40078,600Aug 03 05:24 PM
Black Archie C.CEOAug 01Sale63.3810,000633,76568,600Aug 03 05:24 PM
Black Archie C.CEOJun 01Option Exercise12.0010,000120,00078,600Jun 03 05:53 PM
Black Archie C.CEOJun 01Sale56.0110,000560,05268,600Jun 03 05:53 PM
Black Archie C.CEOMay 02Option Exercise12.0010,000120,00078,600May 04 05:53 PM
Black Archie C.CEOMay 02Sale51.6310,000516,29068,600May 04 05:53 PM
Black Archie C.CEOApr 27Option Exercise12.0010,000120,00078,600Apr 29 05:39 PM
Black Archie C.CEOApr 27Sale50.0010,000500,00068,600Apr 29 05:39 PM
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.20% Shs Outstand123.22M Perf Week-2.63%
Market Cap410.32M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float122.40M Perf Month2.15%
Income-128.50M PEG- EPS next Q-0.29 Inst Own67.90% Short Float15.68% Perf Quarter-12.14%
Sales6.80M P/S60.34 EPS this Y3.40% Inst Trans17.46% Short Ratio10.01 Perf Half Y-10.48%
Book/sh2.46 P/B1.35 EPS next Y4.10% ROA-42.50% Target Price6.60 Perf Year-5.67%
Cash/sh1.54 P/C2.16 EPS next 5Y- ROE-52.60% 52W Range2.85 - 5.13 Perf YTD-5.93%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-50.10% 52W High-35.09% Beta2.72
Dividend %- Quick Ratio5.60 Sales past 5Y-6.00% Gross Margin- 52W Low16.84% ATR0.17
Employees196 Current Ratio5.60 Sales Q/Q5.60% Oper. Margin- RSI (14)47.34 Volatility5.64% 5.59%
OptionableYes Debt/Eq0.00 EPS Q/Q9.60% Profit Margin- Rel Volume0.67 Prev Close3.27
ShortableYes LT Debt/Eq0.00 EarningsMar 14 AMC Payout- Avg Volume1.92M Price3.33
Recom2.30 SMA20-3.31% SMA50-2.82% SMA200-13.80% Volume1,281,042 Change1.83%
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Nov-02-11Reiterated Brean Murray Buy $16 → $14
Mar-21-17 09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 -5.93%
Mar-20-17 10:01AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-18-17 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Mar-17-17 08:10AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 17, 2017
Mar-15-17 10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
12:58AM  Edited Transcript of CLDX earnings conference call or presentation 14-Mar-17 8:30pm GMT
Mar-14-17 06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing at Motley Fool
04:30PM  Celldex Therapeutics Inc Earnings and Corporate Strategy Call scheduled for 4:30 pm ET today
04:26PM  CELLDEX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:14PM  Celldex reports 4Q loss
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2016 Results GlobeNewswire
07:07AM  Q4 2016 Celldex Therapeutics Inc Earnings Release - After Market Close
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-10-17 02:42PM  Better Buy: Agenus Inc. vs. Celldex Therapeutics at Motley Fool
Mar-09-17 09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
Mar-08-17 09:30AM  Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics Accesswire
Mar-07-17 04:43PM  Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why at Motley Fool -9.19%
Mar-06-17 11:03AM  Why Celldex Therapeutics Stock Gained 10% in February at Motley Fool
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
Mar-03-17 08:03AM  3 Stocks That Could Double Your Money at Motley Fool
Mar-01-17 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-23-17 07:44PM  Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years at Motley Fool
Feb-13-17 02:45PM  Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call GlobeNewswire
Feb-09-17 09:48AM  Why Celldex Therapeutics Stock Fell by Almost 10% in January at Motley Fool
Feb-07-17 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Feb-06-17 07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics Accesswire
Feb-01-17 08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-20-17 10:41AM  3 Beaten-Down Biotech Stocks You Can Buy Right Now at Motley Fool
Jan-10-17 10:36AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : January 10, 2017
09:09AM  Why Celldex Therapeutics Imploded in 2016 at Motley Fool
Jan-09-17 07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : January 9, 2017
Jan-06-17 01:26PM  Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 02:51PM  How to Value Clinical-Stage Biotech Stocks at Motley Fool
07:18AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : December 19, 2016
Dec-15-16 02:51PM  Celldex Therapeutics, Inc.'s Biggest Failure in 2016 at Motley Fool
Dec-14-16 04:09PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Dec-13-16 12:22PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Dec-11-16 12:06PM  Celldex Therapeutics, Inc.'s Biggest Win in 2016 at Motley Fool
Dec-10-16 07:32PM  Is Celldex Therapeutics, Inc. (CLDX) a Good Stock To Buy? at Insider Monkey
Dec-08-16 12:23PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2016
Dec-07-16 11:12AM  Is Celldex Therapeutics (CLDX) Stock a Solid Choice Right Now?
10:01AM  Why Celldex Rallied 22% In November at Motley Fool
Dec-06-16 05:53PM  Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc. at Motley Fool
Dec-05-16 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F +6.76%
04:01PM  Theresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team GlobeNewswire
08:01AM  Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-16 01:17PM  The Worst Biotech Stocks of 2016 at Motley Fool
Dec-01-16 07:32AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : December 1, 2016 -6.30%
Nov-29-16 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale
04:01PM  Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals GlobeNewswire
08:17AM  Down 11.7%: Is Celldex Therapeutics Now a Buy? at Motley Fool
Nov-23-16 12:47PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 23, 2016
Nov-22-16 10:27AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-21-16 07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool +5.64%
Nov-15-16 02:24PM  Celldex Cancer Drug Did Well in Early Trial (CLDX) at Investopedia
08:03AM  Celldex Stock Up on Positive Data on New Cancer Candidate
Nov-14-16 03:58PM  Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today at Motley Fool +13.89%
08:01AM  Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody GlobeNewswire
Nov-09-16 04:41PM  Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October at Motley Fool +6.61%
03:45PM  Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
07:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2016
Nov-08-16 12:51PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool +14.89%
10:50AM  Celldex 3Q Loss $30M, or 29 Cents a Share (CLDX) at Investopedia
Nov-07-16 06:21PM  Celldex Therapeutics, Inc. Watches Its Cash in Q3, Ready to Expand at Motley Fool +6.47%
05:31PM  Celldex reports 3Q loss
04:07PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Celldex Reports Third Quarter 2016 Results GlobeNewswire
09:37AM  Coverage initiated on Celldex Therapeutics by Aegis Capital
Nov-03-16 08:49AM  Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay -8.89%
08:15AM  Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million Accesswire
Nov-02-16 01:55PM  Celldex Buys Cancer Drug Co. for $62M Stock (CLDX) at Investopedia
11:33AM  3 Biotech Stocks That Could Double in 12 Months at Motley Fool
09:50AM  9 Biotech Stocks to Put on Your Radar at Kiplinger
Nov-01-16 04:08PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
04:02PM  Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals GlobeNewswire
Oct-31-16 08:50AM  Celldex (CLDX): Will the Stock Surprise in Q3 Earnings?
Oct-26-16 11:15AM  Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc. at Motley Fool
Oct-19-16 11:26AM  ETFs with exposure to Celldex Therapeutics, Inc. : October 19, 2016
07:05AM  Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. at Motley Fool
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 08:02AM  Is This Risky Biotech Stock About to Jump Higher? at Motley Fool
Oct-12-16 08:43AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 12, 2016
Oct-11-16 04:30PM  These 3 Little Biotechs Just Scored Big at Motley Fool -8.96%
09:15AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results Accesswire
09:05AM  Blog Coverage Celldex Phase II Study of Glembatumumabvedotin Show Positive Results
Oct-09-16 07:00AM  Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response GlobeNewswire
Oct-05-16 02:42PM  Three Cancer Plays For The Fourth Quarter Of 2016 at Insider Monkey
02:35PM  4 breakout stocks to watch at MarketWatch
Oct-04-16 05:46PM  Why Endurance Specialty Holdings, Celldex Therapeutics, and Sears Holdings Jumped Today at Motley Fool +6.75%
01:29PM  Why Celldex Therapeutics, Inc. Jumped Higher Today at Motley Fool
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. The company's lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent glioblastoma; Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate (ADC) in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma; and Varlilumab (CDX-1127), an immune modulating antibody is in Phase I study for the treatment of multiple solid tumors. It also has various earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, a fully-human monoclonal ADC that targets T cell immunoglobulin and mucin domain 1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. In addition, the company is developing CDX-0158, which is in a Phase I dose escalation study in refractory gastrointestinal stromal tumors; CDX-3379 that completed a Phase Ib study for adult patients with advanced solid tumors; and a multi-faceted TAM program to generate antibodies that modulate the TAM family of RTKs comprising of Tyro3, AXL, and MerTK. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CATLIN AVERY WSr. VP & CFOSep 02Option Exercise2.8010,00028,00083,586Sep 07 12:59 PM
KELER TIBORExecutive VP & CSOSep 02Buy3.323,0009,96018,868Sep 06 01:04 PM
CATLIN AVERY WSr. VP & CFOJun 03Option Exercise3.0122,84768,81273,586Jun 06 08:26 AM
DAC Danaos Corporation daily Stock Chart
DAC [NYSE]
Danaos Corporation
Index- P/E- EPS (ttm)-3.34 Insider Own58.70% Shs Outstand109.80M Perf Week-17.50%
Market Cap181.17M Forward P/E1.87 EPS next Y0.88 Insider Trans0.00% Shs Float19.58M Perf Month-34.00%
Income-366.20M PEG- EPS next Q0.18 Inst Own2.30% Short Float1.49% Perf Quarter-37.74%
Sales498.30M P/S0.36 EPS this Y-412.90% Inst Trans-6.38% Short Ratio5.37 Perf Half Y-44.07%
Book/sh4.44 P/B0.37 EPS next Y9.32% ROA-10.40% Target Price3.00 Perf Year-59.76%
Cash/sh0.67 P/C2.46 EPS next 5Y3.00% ROE-45.30% 52W Range1.60 - 4.90 Perf YTD-37.74%
Dividend- P/FCF0.69 EPS past 5Y26.24% ROI-7.10% 52W High-66.33% Beta1.04
Dividend %- Quick Ratio0.00 Sales past 5Y1.30% Gross Margin75.30% 52W Low3.12% ATR0.16
Employees1196 Current Ratio0.10 Sales Q/Q-21.80% Oper. Margin-42.70% RSI (14)35.43 Volatility9.30% 8.92%
OptionableNo Debt/Eq5.14 EPS Q/Q- Profit Margin-73.50% Rel Volume0.64 Prev Close1.80
ShortableYes LT Debt/Eq0.00 EarningsFeb 21 AMC Payout- Avg Volume54.44K Price1.65
Recom3.00 SMA20-17.50% SMA50-30.17% SMA200-44.59% Volume34,871 Change-8.33%
Feb-20-15Initiated Global Hunter Securities Neutral
Sep-18-14Resumed Clarkson Capital Hold
Apr-17-13Initiated Global Hunter Securities Neutral
Apr-24-09Downgrade Jefferies & Co Buy → Hold $6 → $5
Mar-13-09Reiterated Jefferies & Co Buy $22 → $6
Nov-04-08Reiterated Jefferies & Co Buy $46 → $22
Jan-29-08Initiated Oppenheimer Outperform $36
Nov-20-07Initiated Lazard Capital Buy $39
Jul-18-07Initiated Credit Suisse Outperform $37
Jan-25-07Reiterated Fortis Bank Buy $23 → $27
Mar-17-17 08:20AM  Danaos (DAC) Shows Strength: Stock Moves 15.2% Higher +5.26%
Mar-16-17 08:23AM  Danaos Corp. :DAC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 +15.15%
Mar-15-17 01:01PM  Danaos Corp. :DAC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
Mar-10-17 01:04PM  DANAOS CORP Financials -5.26%
Mar-06-17 04:58PM  Danaos Corporation Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2016 PR Newswire
Feb-21-17 06:04PM  Danaos reports 4Q loss
04:30PM  Danaos Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2016 PR Newswire
07:07AM  Q4 2016 Danaos Corp Earnings Release - After Market Close
Feb-15-17 04:30PM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2016 Results, Conference Call and Webcast PR Newswire
Dec-22-16 11:07AM  What Makes Danaos (DAC) a Strong Sell?
Dec-16-16 11:30AM  DryShips Shares Float Higher Again With New Loan
Dec-15-16 04:40PM  Danaos reports 3Q loss +5.17%
04:30PM  Danaos Corporation Reports Third Quarter and Nine Months Results for the Period Ended September 30, 2016 PR Newswire
07:07AM  Q3 2016 Danaos Corp Earnings Release - After Market Close
Dec-13-16 04:48PM  Danaos Corporation Announces Date for the Release of Third Quarter 2016 Results, Conference Call and Webcast PR Newswire
Nov-21-16 08:26AM  Shipping Stocks' Q3 Earnings Round the Corner: GOGL, DAC
Nov-16-16 06:08PM  Why Fossil Group, Advanced Micro Devices, and Danaos Jumped Today at Motley Fool +8.96%
03:24PM  Danaos Corp.: Price momentum supported by strong fundamentals
07:39AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : DAC-US : November 16, 2016
Nov-15-16 04:02PM  Why Shipping Stocks Skyrocketed Higher Today at Motley Fool +42.55%
Nov-08-16 09:39AM  Best of the Worst: Can We Find a Container Shipping Company to Invest In? at Motley Fool -8.00%
Nov-07-16 07:27AM  Transport Stock Earnings to Watch on Nov 8 - EXPD, TGH, DAC
Oct-10-16 09:00AM  Capital Link's 6th Annual Operational Excellence & Maritime CSR Forum Wednesday, November 2, 2016 in London, UK Marketwired
Sep-09-16 04:26PM  Danaos Corp.: Price momentum supported by strong fundamentals
Sep-01-16 08:00AM  Danaos Corporation Receives Notice that Counterparty has Entered into Court Receivership PR Newswire -11.46%
Aug-30-16 01:45PM  Will Seaspan Corporation Raise Its Dividend in 2017? at Motley Fool
Aug-18-16 08:09AM  Danaos Corp. breached its 50 day moving average in a Bearish Manner : DAC-US : August 18, 2016
Aug-15-16 04:15PM  3 Things Seaspan Corporation's CEO Wants You to Know at Motley Fool
Aug-11-16 05:24AM  Navigator Holdings (NVGS) in Focus: Stock Up 7% in Session
Aug-10-16 01:11PM  Danaos Corp. :DAC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
08:34AM  Should You Get Rid of Kirby (KEX) Now?
Aug-03-16 09:30AM  Zacks.com featured highlights: Danaos, Telecom Italia, Fibria Celulose, Goodyear Tire & Rubber and Zafgen
08:25AM  Ardmore Shipping (ASC) in Focus: Stock Moves 9.4% Higher
Aug-01-16 05:06PM  Danaos posts 2Q profit
04:30PM  Danaos Corporation Reports Second Quarter and Half Year Results for the Period Ended June 30, 2016 PR Newswire
07:07AM  Q2 2016 Danaos Corp Earnings Release - After Market Close
Jul-29-16 08:39AM  Transport Stocks' Q2 Earnings on Aug 1: DAC, RAIL & Others
Jul-25-16 08:51AM  What Makes Navigator Holdings (NVGS) a Strong Sell?
Jul-21-16 04:30PM  Danaos Corporation Announces Date for the Release of Second Quarter 2016 Results, Conference Call and Webcast Marketwired
Jul-20-16 08:05AM  Star Bulk Carriers (SBLK) in Focus: Stock Up 5.3% in Session +5.57%
Jul-19-16 09:30AM  Zacks.com featured highlights: Stamps.com, ReneSola and Danaos
08:30AM  Capital Product (CPLP) Soars: Stock Adds 7.6% in Session
Jul-18-16 03:39PM  Danaos Corp. Value Analysis (NYSE:DAC) : July 18, 2016 +7.43%
Jul-12-16 06:53AM  Can the Rally in Danaos (DAC) Shares Continue?
Jul-11-16 08:54AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : DAC-US : July 11, 2016 +5.94%
Jul-08-16 08:35AM  Aegean Marine Petroleum (ANW) in Focus: Stock Jumps 5.6% +23.17%
08:05AM  3 Reasons Why Danaos Corporation (DAC) is a Great Value Stock
Jul-07-16 08:58AM  Why Scorpio Tankers (STNG) Could Be Positioned for a Slump +11.19%
08:25AM  Danaos (DAC) Shows Strength: Stock Adds 8.5% in Session
Jun-21-16 10:29AM  Maersk battles to stay on top as container shipping downturn deepens
Jun-17-16 03:15PM  Seaspan Corporation Refuses to Throw a Lifeline to a Sinking Customer at Motley Fool
May-31-16 10:05AM  Has Seaspan Corporation Done Enough to Shore Up Its Finances? at Motley Fool
May-23-16 04:14PM  Danaos Corp.: Price momentum supported by strong fundamentals -5.48%
May-10-16 09:05AM  Industry Leaders at Capital Link's Analyst & Investor Day on June 6, 2016 at Athens, Greece Marketwired
May-06-16 11:29AM  Danaos Corp. :DAC-US: Earnings Analysis: Q1, 2016 By the Numbers -12.95%
May-04-16 06:42PM  Danaos posts 1Q profit +6.10%
04:30PM  Danaos Corporation Reports First Quarter Results for the Period Ended March 31, 2016 Marketwired
07:07AM  Q1 2016 Danaos Corp Earnings Release - After Market Close
Apr-21-16 04:39PM  Danaos Corporation Announces Date for the Release of First Quarter 2016 Results, Conference Call and Webcast Marketwired
Mar-29-16 04:14PM  Greek Billionaire George Economou Buys More Shares of Danaos Corp (DAC) at Insider Monkey
Mar-18-16 08:30AM  Danaos Corporation Announces Availability of Its Annual Report on Form 20-F for the Year Ended December 31, 2015 Marketwired
Feb-18-16 10:28AM  Danaos Corp. Earnings Analysis: 2015 By the Numbers
Feb-16-16 05:23PM  Danaos beats 4Q profit forecasts
04:46PM  Danaos Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2015 Marketwired
07:07AM  Q4 2015 Danaos Corp Earnings Release - After Market Close
Feb-10-16 09:30AM  New Strong Buy Stocks for February 10th
Feb-02-16 05:24PM  Danaos Corp. Value Analysis (NYSE:DAC) : February 2, 2016
08:05AM  Navigator Holdings (NVGS) in Focus: Stock Rises 6.5%
08:02AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : February 2, 2016
Feb-01-16 09:10AM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2015 Results, Conference Call and Webcast at noodls
09:00AM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2015 Results, Conference Call and Webcast Marketwired
Jan-22-16 08:30AM  KNOT Offshore Partners (KNOP) Jumps: Stock Rises 6.7%
Jan-21-16 08:40AM  Capital Product Partners (CPLP) Jumps: Stock Rises 5.6%
Jan-15-16 02:43PM  Edited Transcript of DAC earnings conference call or presentation 4-Nov-15 2:00pm GMT -5.49%
Jan-13-16 09:30AM  The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Jan-12-16 02:18PM  5 Smart PIIGS Stocks to Buy Now
Jan-01-16 08:01AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : January 1, 2016
Dec-31-15 04:13PM  Danaos Corp.: Strong price momentum but will it sustain? +8.12%
08:25AM  Danaos Corporation (DAC) Looks Good: Stock Adds 14.9%
Dec-30-15 08:30AM  Diana Containerships (DCIX) Looks Good: Stock Up 5.3% +14.94%
Dec-18-15 09:48AM  Danaos Corp. Earnings Analysis: Q3, 2015 By the Numbers
08:30AM  Teekay Corporation (TK) in Focus: Stock Plunges 58.4%
Dec-14-15 08:55AM  Danaos Corp Stock: 3 Reasons Why DAC Is a Top Choice for Value Investors
Dec-09-15 08:05AM  Navios Maritime (NMM) in Focus: Stock Moves 15.1% Higher
Dec-08-15 02:28PM  REMINDER - Capital Link's 9th Annual Global Shipping Markets Roundtable Marketwired
08:42AM  Teekay Offshore (TOO) Crumbles: Stock Falls by 11.9%
08:36AM  Weakness Seen in Teekay LNG (TGP): Stock Slumps 12.8%
Dec-02-15 09:12AM  Capital Link's 9th Annual Global Shipping Markets Roundtable Marketwired
Nov-23-15 05:18PM  Beyond Virgin America: 4 Transportation Stocks That Hold Promise
Nov-16-15 09:30AM  The Zacks Analyst Blog Highlights: Huaneng Power International, Danaos, Tesoro, General Motors and Marathon Petroleum
Nov-13-15 08:47AM  Better Safe than Sorry: Buy These 5 Stocks with P/Es Below 10
08:34AM  Can Danaos (DAC) Keep the Earnings Streak Alive This Quarter?
Nov-10-15 11:04AM  Danaos Corp. breached its 50 day moving average in a Bearish Manner : November 10, 2015
Nov-03-15 05:43PM  Danaos tops Street 3Q forecasts
04:15PM  Danaos Corporation Reports Third Quarter and Nine Months Results for the Period Ended September 30, 2015 Marketwired
07:07AM  Q3 2015 Danaos Corp Earnings Release - After Market Close
Oct-29-15 09:28AM  Danaos Corp. breached its 50 day moving average in a Bearish Manner : October 29, 2015
Oct-21-15 11:56AM  23 Shipping & Offshore Companies Presenting at Capital Link's Operational Excellence - Sustainability Forum Marketwired
Oct-13-15 04:15PM  Danaos Corporation Announces Date for the Release of Third Quarter 2015 Results, Conference Call and Webcast Marketwired
Oct-09-15 09:30AM  The Zacks Analyst Blog Highlights: Scientific Games, Exterran Partners, Matson, Danaos and Spectra Energy Partners
Danaos Corporation, together with its subsidiaries, owns and operates containerships in Australia, Asia, and Europe. The company offers seaborne transportation services, such as chartering its vessels to liner companies. As of February 28, 2017, it had a fleet of 55 containerships aggregating 329,588 twenty foot equivalent units. The company was formerly known as Danaos Holdings Limited and changed its name to Danaos Corporation in October 2005. Danaos Corporation was founded in 1972 and is based in Piraeus, Greece.